Research Studies

Cancer Center Research Studies

Find research studies available to children cared for by the Cancer Center team.
Existing patients or family members
New patients, referrals and second opinions

Search Research Studies

Clinical trial
Children (29)
Adults (23)
MRI/Imaging Studies (3)

Clinical Trial Phases
Phase I (14)
Phase II (20)
Phase III (3)
N/A (2)

Recruitment Status
Recruiting (25)
Non-recruiting (4)

Related Specialties and Programs
Cancer Center (29)
Solid Tumor Program (17)
Comprehensive Vascular Anomalies Program (CVAP) (4)
Leukemia and Lymphoma Program (4)
Relapsed Leukemia and Lymphoma Program (3)
Cancer Immunotherapy Program (1)
Dermatology Section (1)
Interventional Radiology (1)

Specialty
Dermatology (1)
Oncology (29)
Radiology (1)

Selpercatinib in Thyroid Cancer (Collaboration with the International Thyroid Oncology Group)
This study involves taking a study drug called selpercatinib. The overall goal of this study is to find out how effective the study drug is in combination with radioactive iodine (I-131) in treating people with thyroid cancer. The study drug will be given in combination with treatments you will receive as part of your regular cancer care (I-131 and thyrotropin alfa). 

Phase: Phase II

Actively recruiting: Yes

Category: Adults, Children

Selpercatinib RAI Thyroid (RAISE Trial)
This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and RET fusion. The study involves taking a study drug called selpercatinib for approximately 6 months prior to receiving radioiodine therapy (RAI). The overall goal of this study is to find out if taking the study drug before RAI works better than receiving RAI alone (the usual standard of care treatment). 

Phase: Phase II

Actively recruiting: Yes

Category: Adults, Children, MRI/Imaging Studies

Synovial Sarcoma Registry/Biospecimen Repository

The Synovial Sarcoma Registry and Biospecimen Repository was opened in June of 2023 with the goal of furthering research and improving outcomes for patients with synovial sarcoma. This study is open to anyone treated in the United States. You do NOT have to travel to Philadelphia to participate.

Actively recruiting: Yes

Category: Adults, Children

T2017-002 TACL Ixazomib Study
CHOP and the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium is conducting a study for children and young adults 21 years old or younger who have relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. This study adds the study drug 'Ixazomib' to standard relapsed ALL chemotherapy drugs. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT03817320" or visit the TACL website at https://tacl.chla.usc.edu/Tacl/#!/Page/3. To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.

Phase: Phase I, Phase II

Actively recruiting: Yes

Category: Adults, Children

TAPISTRY

The purpose of this study is to evaluate the effects, good or bad, of targeted therapies or immunotherapy (drugs that help the body's immune system fight cancer cells) in patients who have solid tumors with specific genetic alterations or with a high number of mutations. Patients will be assigned to cohorts (groups) based on having a specific type of genetic alteration in their tumor. The study includes cohorts for patients whose tumors have genetic alterations in the ROS1, NTRK, PIK3CA, BRAF, or RET genes or a high number of mutations in their tumor.

Phase: Phase II

Actively recruiting: No

Category: Adults, Children

Tara-002 in Lymphatic Malformations
This study is for people with growing abnormal lymph vessels called lymphatic malformations (LMs). This study has 3 parts and involves taking a study drug called TARA-002. The purpose of this study is to find out if the study drug is safe and effective (can help) people with LMs. Participants receive the study drug by injection and will complete other research assessments throughout the study. 

Phase: Phase II

Actively recruiting: Yes

Category: Children

Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids
This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory"). Part B enrolls patients with a relapsed or refractory Ewing sarcoma, desmoid tumor, osteosarcoma, liver tumor, Wilms tumor, or tumors with changes in a gene family known as the Wnt pathway. This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose. 

Phase: Phase I, Phase II

Actively recruiting: Yes

Category: Adults, Children

Tiragolumab and Atezolizumab in SMARCB1 or SMARCA4 Deficient Tumors
This study enrolls patients that have been diagnosed with SMARCB1 or SMARCB4 deficient cancer that has either come back (“relapsed”) or does not respond to therapy (“is refractory”) or have been newly diagnosed with a SMARCB1 or SMARCB4 deficient cancer that has no known standard treatment. This study involves taking study drugs called tiragolumab and atezolizumab. These drugs are a type of immunotherapy that try to make the immune system fight cancer. The purpose of the study is to learn more about the safety of tiragolumab in children and to see how well the combination of tiragolumab and atezolizumab works when given to children and adults with these types of tumors. This study has two parts. In Part A, participants will receive tiragolumab. In Part B, participants will receive both tiragolumab and atezolizumab. 

Phase: Phase I, Phase II

Actively recruiting: Yes

Category: Adults, Children

Uproleselan in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or Mixed Phenotype Acute Leukemia (MPAL)
This study enrolls patients that have been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or mixed phenotype acute leukemia (MPAL) that has either come back (‘relapsed’) or does not respond to therapy (‘refractory’). This study involves taking a drug called uproleselan that is not yet approved for use in children or adults. The purpose of the study is to find a safe dose of the study drug in children that can be given with standard chemotherapy without causing severe side effects. 

Phase: Phase I

Actively recruiting: No

Category: Children